The multinational conglomerate Fujifilm will invest $1.6 billion to improve and ramp up the cell culture manufacturing services of its CDMO subsidiary Fujifilm Diosynth Biotechnologies.
Most of the investment will focus on a site in Hillerød, Denmark. A site in College Station, Texas, will also benefit from a funding injection.
The investment will increase the capacity of its cGMP batch manufacturing with the addition of eight 20,000L bioreactors and two downstream processing streams.
Fujifilm boasts that the Hillerød facility will be the largest end-to-end CDMO in Europe with 20 x 20,000L bioreactors for drug substance production.
The Denmark facility will also have sustainable production features. For example, it will use an electric boiler rather than one powered by natural gas. Fujifilm Diosynth Biotechnologies also will invest in technologies to curb water consumption.
Fujifilm expects the investment to create roughly 450 jobs. There a…